ArticleSmart molecules : open access2024
Metallo-supramolecular nanofibers based on type-I photosensitizer for synergistic antibacterial therapy.
Article in Smart molecules : open access, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Innovative 3D-bioprinted microfibers in calcium phosphate cement platform with Nell-1 to activate nerve-bone axis for synergistic bone, vasculature, and nanofibrous nerve regeneration.Smart molecules : open access · 2026Article
- Electroresponsive Strategies to Combat Bacterial Infections.Research (Washington, D.C.) · 2026Review
- Advanced applications of cationic photosensitizer DHPC in photodynamic eradication of drug-resistant bacteria.Frontiers in microbiology · 2026Article
- Development of a Methylene Blue Carrier System in Gellan Gum for Application in Antimicrobial Photodynamic Therapy againstACS omega · 2025Article
- A Photon-Driven Unimolecular Immunostimulant for Self-Amplified Pyroptosis and cGAS-STING Pathway by Destroying the Pyroptosis Checkpoint.Angewandte Chemie (International ed. in English) · 2025Article
- Metallo-supramolecular nanofibers based on type-I photosensitizer for synergistic antibacterial therapy.Smart molecules : open access · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photodynamic therapy (PDT) has shown great merits in treating microbial infections due to its absence of bacterial resistance. However, the pronounced hypoxic microenvironment in the bacterial infections limits the therapeutic efficiency of traditional type-II PDT, which is highly dependent on oxygen. Here type-I photosensitizer BTZ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.